Home / Resource Library / Rationale for oncedaily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Rationale for oncedaily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Study examined dosing schedules of zanubrutinib in patients with relapsed mantle cell lymphoma.